Close Menu

NEW YORK ─ Antegenes said on Wednesday that it has received CE marking for four polygenic risk score (PRS) tests ─ AnteBC for breast cancer, AntePC for prostate cancer, AnteCRC for colorectal cancer, and AnteMEL for melanoma.

The Estonia-based biotech company has launched the tests for use in the European Union and other countries that accept the designation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.